-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Avalo Therapeutics (NASDAQ:AVTX) Versus Forward Pharma A/S (NASDAQ:FWP) Head-To-Head Contrast
Avalo Therapeutics (NASDAQ:AVTX) Versus Forward Pharma A/S (NASDAQ:FWP) Head-To-Head Contrast
Forward Pharma A/S (NASDAQ:FWP – Get Rating) and Avalo Therapeutics (NASDAQ:AVTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
Earnings and Valuation
This table compares Forward Pharma A/S and Avalo Therapeutics' top-line revenue, earnings per share and valuation.
Get Forward Pharma A/S alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Forward Pharma A/S | N/A | N/A | -$1.89 million | N/A | N/A |
Avalo Therapeutics | $5.40 million | 7.72 | -$84.38 million | N/A | N/A |
Forward Pharma A/S has higher earnings, but lower revenue than Avalo Therapeutics.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Forward Pharma A/S and Avalo Therapeutics, as reported by MarketBeat.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Forward Pharma A/S | 0 | 0 | 0 | 0 | N/A |
Avalo Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
Avalo Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 577.20%. Given Avalo Therapeutics' higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Forward Pharma A/S.
Volatility & Risk
Forward Pharma A/S has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Profitability
This table compares Forward Pharma A/S and Avalo Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Forward Pharma A/S | N/A | N/A | N/A |
Avalo Therapeutics | -1,896.95% | -449.27% | -106.25% |
Institutional & Insider Ownership
13.0% of Forward Pharma A/S shares are held by institutional investors. 71.5% of Forward Pharma A/S shares are held by insiders. Comparatively, 45.4% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Forward Pharma A/S beats Avalo Therapeutics on 7 of the 10 factors compared between the two stocks.
About Forward Pharma A/S
(Get Rating)
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
About Avalo Therapeutics
(Get Rating)
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
Forward Pharma A/S (NASDAQ:FWP – Get Rating) and Avalo Therapeutics (NASDAQ:AVTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
前進醫藥A/S(納斯達克:FWP-GET評級)和阿瓦洛治療(納斯達克:AVTX-GET評級)都是小盤醫療公司,但哪一家更好?我們將根據分析師建議的實力、盈利能力、股息、估值、風險、收益和機構所有權對這兩家公司進行比較。
Earnings and Valuation
收益和估值
This table compares Forward Pharma A/S and Avalo Therapeutics' top-line revenue, earnings per share and valuation.
此表比較了Forward Pharma A/S和Avalo Treeutics的營收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Forward Pharma A/S | N/A | N/A | -$1.89 million | N/A | N/A |
Avalo Therapeutics | $5.40 million | 7.72 | -$84.38 million | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
正向醫藥應收賬款 | 不適用 | 不適用 | -189萬元 | 不適用 | 不適用 |
阿瓦洛治療公司 | 540萬美元 | 7.72 | -8,438萬元 | 不適用 | 不適用 |
Forward Pharma A/S has higher earnings, but lower revenue than Avalo Therapeutics.
Forward Pharma A/S的收益高於Avalo治療公司,但收入低於Avalo治療公司。
Analyst Recommendations
分析師建議
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Forward Pharma A/S | 0 | 0 | 0 | 0 | N/A |
Avalo Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
正向醫藥應收賬款 | 0 | 0 | 0 | 0 | 不適用 |
阿瓦洛治療公司 | 0 | 1 | 2 | 0 | 2.67 |
Avalo Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 577.20%. Given Avalo Therapeutics' higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Forward Pharma A/S.
阿瓦洛治療公司的共識目標價為30美元,暗示潛在上漲577.20%。考慮到Avalo治療公司更有可能的上行空間,分析師們顯然認為Avalo治療公司比Forward Pharma A/S更有利。
Volatility & Risk
波動性與風險
Forward Pharma A/S has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Forward Pharma A/S的貝塔係數為1.36,這意味着其股價的波動性比標準普爾500指數高36%。相比之下,Avalo Treateutics的貝塔係數為1.3,這意味着其股價的波動性比標準普爾500指數高30%。
Profitability
盈利能力
This table compares Forward Pharma A/S and Avalo Therapeutics' net margins, return on equity and return on assets.
此表比較了Forward Pharma A/S和Avalo Treeutics的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Forward Pharma A/S | N/A | N/A | N/A |
Avalo Therapeutics | -1,896.95% | -449.27% | -106.25% |
淨利潤率 | 股本回報率 | 資產回報率 | |
正向醫藥應收賬款 | 不適用 | 不適用 | 不適用 |
阿瓦洛治療公司 | -1,896.95% | -449.27% | -106.25% |
Institutional & Insider Ownership
機構與內部人持股
13.0% of Forward Pharma A/S shares are held by institutional investors. 71.5% of Forward Pharma A/S shares are held by insiders. Comparatively, 45.4% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
機構投資者持有13.0%的Forward Pharma A/S股票。71.5%的Forward Pharma A/S股份由內部人士持有。相比之下,Avalo Treateutics 45.4%的股份由內部人士持有。強大的機構持股表明,捐贈基金、大型基金管理公司和對衝基金相信,一家公司的長期表現將好於大盤。
Summary
摘要
Forward Pharma A/S beats Avalo Therapeutics on 7 of the 10 factors compared between the two stocks.
Forward Pharma A/S在兩隻股票比較的10個因素中有7個擊敗了Avalo Treateutics。
About Forward Pharma A/S
關於Forward Pharma A/S
(Get Rating)
(獲取評級)
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Forward Pharma A/S沒有重大操作。此前,它是一家生物製藥公司,專注於開發用於治療炎症和神經系統適應症的富馬酸二甲酯的FP187專利配方。Forward Pharma A/S成立於2005年,總部設在丹麥哥本哈根。
About Avalo Therapeutics
關於Avalo Treateutics
(Get Rating)
(獲取評級)
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Avalo治療公司是一家臨牀階段的精密藥物公司,為免疫學、免疫腫瘤學和罕見遺傳病方面未得到滿足的臨牀需求的患者發現、開發和商業化靶向治療藥物。該公司開發了AVTX-002,這是一種完全人類抗光的單抗,正在進行第二階段臨牀試驗,用於治療非嗜酸性哮喘以及炎症性腸道疾病,包括中到重度克羅恩病和潰瘍性結腸炎;以及第三階段臨牀試驗,用於治療新冠肺炎急性呼吸窘迫綜合徵。該公司還致力於開發AVTX-007,這是一種完全人類抗IL-18的單抗,正在進行第一階段臨牀試驗,用於治療斯蒂爾病,包括成人發病的斯蒂爾病和全身性幼年特發性關節炎。它的第三階段臨牀試驗中針對罕見遺傳病的產品包括治療磷酸葡萄糖變位酶1缺乏症(PGM1)的D-半乳糖底物替代療法AVTX-801,也稱為PGM1-CDG;以及治療LADII的L-巖藻糖底物替代療法AVTX-803,也稱為SLC35C1-CDG。該公司前身為Cerecor Inc.,並於2021年8月更名為Avalo治療公司。Avalo治療公司成立於2011年,總部設在馬裏蘭州羅克維爾。
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接受Forward Pharma A/S日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Forward Pharma A/S和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧